Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases.

Nirula A, Nilsen J, Klekotka P, Kricorian G, Erondu N, Towne JE, Russell CB, Martin DA, Budelsky AL.

Rheumatology (Oxford). 2016 Dec;55(suppl 2):ii43-ii55. Review.

2.

New treatment targets for axial spondyloarthritis.

Sieper J.

Rheumatology (Oxford). 2016 Dec;55(suppl 2):ii38-ii42. Review.

3.

New targets in psoriatic arthritis.

Braun J.

Rheumatology (Oxford). 2016 Dec;55(suppl 2):ii30-ii37. Review.

4.

Secukinumab for ankylosing spondylitis and psoriatic arthritis.

Lubrano E, Perrotta FM.

Ther Clin Risk Manag. 2016 Oct 21;12:1587-1592. Review.

5.

Treatment challenges in the management of moderate-to-severe plaque psoriasis - role of secukinumab.

Malakouti M, Jacob SE, Anderson NJ.

Clin Cosmet Investig Dermatol. 2016 Oct 11;9:347-355. Review.

6.
7.

Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases.

Wasilewska A, Winiarska M, Olszewska M, Rudnicka L.

Postepy Dermatol Alergol. 2016 Aug;33(4):247-52. doi: 10.5114/ada.2016.61599. Review.

8.

The Patient's Guide to Psoriasis Treatment. Part 3: Biologic Injectables.

Abrouk M, Nakamura M, Zhu TH, Farahnik B, Singh RK, Lee KM, Jose MV, Koo J, Bhutani T, Liao W.

Dermatol Ther (Heidelb). 2016 Sep;6(3):325-31. doi: 10.1007/s13555-016-0131-8. Review.

9.

Secukinumab for rheumatology: development and its potential place in therapy.

Koenders MI, van den Berg WB.

Drug Des Devel Ther. 2016 Jun 24;10:2069-80. doi: 10.2147/DDDT.S105263. Review.

10.

Secukinumab.

[No authors listed]

Aust Prescr. 2016 Apr;39(2):64-6. doi: 10.18773/austprescr.2016.011. Review. No abstract available.

11.

Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective.

Mantovani L, Medaglia M, Piacentini P, Tricca M, Vena GA, Vozza A, Castellino G, Roccia A.

Dermatol Ther (Heidelb). 2016 Jun;6(2):151-67. doi: 10.1007/s13555-016-0114-9. Review.

12.

Comparative Effectiveness of Biologic Therapy Regimens for Ankylosing Spondylitis: A Systematic Review and a Network Meta-Analysis.

Chen C, Zhang X, Xiao L, Zhang X, Ma X.

Medicine (Baltimore). 2016 Mar;95(11):e3060. doi: 10.1097/MD.0000000000003060. Review.

13.

Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies.

Elyoussfi S, Thomas BJ, Ciurtin C.

Rheumatol Int. 2016 May;36(5):603-12. doi: 10.1007/s00296-016-3436-0. Review.

14.

A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis.

Campa M, Mansouri B, Warren R, Menter A.

Dermatol Ther (Heidelb). 2016 Mar;6(1):1-12. doi: 10.1007/s13555-015-0092-3. Review. Erratum in: Dermatol Ther (Heidelb). 2016 Jun;6(2):305.

15.

Profile of secukinumab in the treatment of psoriasis: current perspectives.

Roman M, Madkan VK, Chiu MW.

Ther Clin Risk Manag. 2015 Dec 2;11:1767-77. doi: 10.2147/TCRM.S79053. Review.

16.

Interleukin-17 targeted therapies in axial spondyloarthritis.

Wendling D.

Immunotherapy. 2015;7(11):1125-8. doi: 10.2217/imt.15.85. Review. No abstract available.

17.
18.

Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis.

Nast A, Jacobs A, Rosumeck S, Werner RN.

J Invest Dermatol. 2015 Nov;135(11):2641-8. doi: 10.1038/jid.2015.206. Review.

19.

The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications.

Marinoni B, Ceribelli A, Massarotti MS, Selmi C.

Auto Immun Highlights. 2014 Jan 22;5(1):9-19. doi: 10.1007/s13317-013-0057-4. Review.

20.

Dermatology update: The dawn of targeted treatment.

Fernandez A.

Cleve Clin J Med. 2015 May;82(5):309-20. doi: 10.3949/ccjm.82gr.15002. Review.

Items per page

Supplemental Content

Loading ...
Support Center